BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 21274504)

  • 1. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
    Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T
    Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition.
    Khan S; Komarya SK; Jena G
    Epigenomics; 2017 May; 9(5):711-720. PubMed ID: 28470097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylases in cardiovascular and metabolic diseases.
    Bagchi RA; Weeks KL
    J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
    Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
    Cells; 2021 May; 10(6):. PubMed ID: 34071497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW
    Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues.
    Kumar KK; Aburawi EH; Ljubisavljevic M; Leow MKS; Feng X; Ansari SA; Emerald BS
    Clin Epigenetics; 2024 Jun; 16(1):78. PubMed ID: 38862980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.
    Cantley MD; Haynes DR
    Inflammopharmacology; 2013 Aug; 21(4):301-7. PubMed ID: 23341163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
    Sharma S; Taliyan R
    Pharmacol Res; 2016 Nov; 113(Pt A):320-326. PubMed ID: 27620069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
    Ceccacci E; Minucci S
    Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities.
    Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM
    Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.
    Khan S; Jena G
    Epigenomics; 2015; 7(4):669-80. PubMed ID: 26111036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of HDAC inhibitors in diabetes mellitus.
    Makkar R; Behl T; Arora S
    Curr Res Transl Med; 2020 Apr; 68(2):45-50. PubMed ID: 31477543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.
    Hornig E; Heppt MV; Graf SA; Ruzicka T; Berking C
    Exp Dermatol; 2016 Nov; 25(11):831-838. PubMed ID: 27792246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function of histone deacetylase inhibitors in inflammation.
    Grabiec AM; Tak PP; Reedquist KA
    Crit Rev Immunol; 2011; 31(3):233-63. PubMed ID: 21740352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
    Zhou L; He X; Gao B; Xiong S
    J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.
    Marks PA
    Biochim Biophys Acta; 2010; 1799(10-12):717-25. PubMed ID: 20594930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
    Meier BC; Wagner BK
    Epigenomics; 2014 Apr; 6(2):209-14. PubMed ID: 24811789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.
    Algate K; Haynes D; Fitzsimmons T; Romeo O; Wagner F; Holson E; Reid R; Fairlie D; Bartold P; Cantley M
    J Cell Biochem; 2020 Jan; 121(1):244-258. PubMed ID: 31222845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.